预先药物遗传学检测的有意义使用和临床效用：（重新）审视 CYP2D6 弱代谢者的观点。

Meaningful use and clinical utility of preemptive pharmacogenetic testing: (re)view from a CYP2D6 poor metabolizer.

机构信息

Marion Merrell Dow/Missouri Endowed Chair in Pediatric Clinical Pharmacology, Director, Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Professor of Pediatrics and Pharmacology, Schools of Medicine and Pharmacy, University of Missouri-Kansas City, Missouri, USA.

出版信息

Clin Pharmacol Ther. 2015 Feb;97(2):119-21. doi: 10.1002/cpt.14. Epub 2014 Dec 15.

DOI:10.1002/cpt.14

PMID:25670513

Abstract

The value of pharmacogenetic information at an individual level seems self-evident; demonstrating the value to the individual across a population appears to be much more difficult to demonstrate. Future studies should avoid single gene-drug pairs and a limited number of population-specific alleles that are insufficient to capture all relevant genetic variation within diverse populations, such as CYP2C9*2 and *3. Robust associations between cytochrome P450 (CYP) genotypes and treatment response require knowledge of drug exposure.

摘要

个体层面的药物遗传学信息的价值似乎不言而喻；然而，要在人群中证明其对个体的价值似乎要困难得多。未来的研究应避免使用单一基因-药物对和数量有限的特定于人群的等位基因，因为这些等位基因不足以捕捉不同人群中所有相关的遗传变异，例如 CYP2C9*2 和 *3。要了解药物暴露情况，才能确定细胞色素 P450（CYP）基因型与治疗反应之间的可靠关联。